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Lysosome – central role in cell metabolism
The biochemical and cellular basis of lysosomal storage disorders
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Clinical Symptoms
Diagnosis
Lysosomal Disorders and Common Therapeutic Approaches
Molecular and cellular characterization of lysosomal diseases: diversity, frequency and causality
•“Prognosis and prevention in a few inherited diseases existing in the Portuguese population”
PIC/IC/82822/2007.
• “Molecular analysis of the mucolipidosis II and III in Portugal: characterization of the mutational
spectrum and relationship with clinical phenotypes”. PIC/IC/83252/2007
•“The sorting and trafficking of lysosomal proteins through M6P independent pathways: molecular,
biochemical and functional studies”. PTDC/SAL-GMG/102889/2008
Development of alternative therapeutic approaches
• “Splicing therapeutics for patients affected by a lysossomal storage disorders”. (FCT
Research Lines/Projects
SFRH/BD/64592/2009). ”
• Development of a U1 snRNA-adapted gene therapeutic strategy to correct 5’ splicing defects in
lysosomal storage disorders”. SPDM/Genzyme Grant.
• Less is more - Substrate Reduction Therapy for Mucopolysaccharidoses through RNAi. Fundação
Millennium bcp grant.
• Cost action BM1207 – Networking towards application of antisense mediated exon skipping (2013-
2017).
Other projects
• Use of next generation sequencing, for the study of patients presenting symptoms frequently
associated with LSDs, but without a specific diagnosis.
• Development of iPSCs as disease specific cellular models for LSDs
Molecular and cellular characterization of lysosomal diseases: diversity, frequency and causality
Mucopolysaccharidoses type II
16 unrelated Portuguese patients; 
15 different mutations;
9 of the 15 affected the usual splicing pattern at 
the locus.
Functional analysis of IDS splicing defects
IDS gene presents alternative splicing: 11 different transcripts
Complex underlying regulatory mechanism that probably requires the interaction of multiple
splicing factors, and make this gene prone to the occurrence of mutations that disrupt splicing
c.257C>T and c.241C>T (exon 3, IDS gene)
Through overexpression or depletion assays, we experimentally demonstrated that SC35
and hnRNP E1 proteins are involved respectively, in the use and repression of the 
constitutive 3’ splice-site of exon 3.
Matos L et al. (2014) under preparation 
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Mucopolysaccharidoses type IIIA e IIIB
11 Portuguese patients; 
5 novel mutations. 
Frequent mutation: R234C (also in Spanish patients) 
Haplotypic analysis: sharing of the an ancestral 
haplotype by Portuguese and Spanish patients - a 
common origin of the mutation in Iberia (recent).
Mucopolysaccharidoses type IIIC 
3 patients; 
2 novel mutations. 
Sialidosis Galactosialidosis and Glangliosidosis type 1
21 Portuguese patients studied: 
3 affected with sialidosis (NEU1) , 
4 with Galactosialidosis (PPGB) and 
14 with Glangliosidosis type 1 (GLB1)
Several novel missense mutations were reported
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Mucolipidosis type II and III
. A set of 23 unrelated ML II and III cases from several origins was screened:
18 different mutations → 16 in the GNPTG gene and 2 in the GNPTG gene.
Of those, 13 were novel: 11 in the GNPTAB gene and 2 in the GNPTG gene.
• Identification of the first large deletion in the GNPTAB gene
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Origin and spread of a common deletion c.3503_3504delTC 
44 patients and 16 carriers from different geographic 
regions were analyzed for 
3 intragenic polymorphisms and 
2 microsatellite markers flanking the GNPTAB
gene. 
A common haplotype was identified in all chromososmes
bearing the deletion:  common origin (aprox. 2000 years ago)
Its geographical distribution also suggested it to have 
arisen in the  peri-Mediterranean region.
Nonsense/ Frameshift Missense
Missense and frameshift mutations that 
are associated with a severe clinical 
phenotype cause retention of the 
encoded protein in the endoplasmic 
reticulum in its precursor form
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120 individuals with clinical suspicion of LSD but
without definitive biochemical and/or molecular
diagnosis,
no novel mutations were detected either on the
SCARB2 or on the SORT1 genes.
SCARB2 
SORT1
LSD patients without specific diagnosis
Molecular screening of genes involved in mannose 
6-phosphate independent trafficking
Molecular and biochemical characterization of LSDs patients and pathophysiological mechanisms
SCARB2 mutations as phenotypic modifiers in Gaucher disease
To evaluate the role of SCARB2 mutations on the Gaucher
Disease phenotype, the whole cohort of Portuguese GD
patients (which totalizes 91 individuals) was screened and 1
novel mutation in the SCARB2 gene identified.
T398M
Coutinho MF (2014) under preparation
Unverricht- Lundborg
Unverricht- Lundborg disease (ULD ou EPM1, MIM 254800), is a myoclonic epilepsy, 
caused by mutations in the CSTB gene which lead to impaired function of cystatin B and 
failure in the inhibition of lysosomal proteases. 
•Identification of a rare molecular mechanism causal of Unverricht Lundborg disease in 
a unique Portuguese patient.
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Project FCT: PIC/IC/82822/2007 (2010-2013), IR: Olga Amaral
Unverricht-Lundborg disease is caused by mutations in the cystatin B gene
compromising its protective anti-protease function. The normal protein has
several cellular localizations, it is found in the nucleus, cytosol and lysosome.
A B C
CT P
Cystatin B (A-12)
~ 12 KDa
Fig 1: Western analysis of
Molecular and cellular characterization of normal and mutant cystatin B
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• What is the pathogenic mechanism involved in this progressive epilepsy?
• What is the extent of lysosomal involvement?
• In patient fibroblasts the protein quantity is clearly reduced (Fig.1 and Fig.2)
although its location seems to be preserved. Could there be differences in other
cell types?
CSTB: CSTB:
A) control; B) patient; C) CSTB/LAMP:patient
skin fibroblasts of control
and patient
Fig 2: IF study in skin fibroblasts with specific antibodies
Project FCT: PIC/IC/82822/2007 (2010-2013), IR: Olga Amaral
Mucopolysaccharidosis type I (MPS I) results from the defective 
activity of the lysosomal α-L-iduronidase enzyme (IDUA; EC 3.2.1.76). 
MPS I is one of the more frequent MPSs. In the Portuguese 
population it is often associated with mutation W402X (over 60% in 
unrelated patients). 
Caracterization of the IDUA gene mutation W402X (Diogo Ribeiro, MSc)
•Mutation W402X results 
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in NMD, seems amenable 
to correction by nonsense 
suppression. 
•Presence of different 
haplotypes in Portugal
Project FCT: 
PIC/IC/82822/2007 (2010-
2013), IR: Olga Amaral
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- Development of low cost mutation detection techniques 
(Diogo Ribeiro et al. 2011; 2013)
- Identification of rare variants which influence prognosis 
(Ana Duarte et al. 2013; Amaral et al. 2013; Rodrigues et al, 2004)
- Clarifying molecular basis of Lysosomal Diseases (Amaral, 
et al. 1997, 1999 & 2000; Ribeiro, et al. 2001; Pinto et al. 2010)
- Prevalence of various disease causing mutations in 
different populations  (Amaral, et al. 1994; Marcao, et al. 1999; 
Pinto et al. 2004; Lugowska et al. 2005; Cherif et al. 2009 & 2013) 
Project FCT: PIC/IC/82822/2007 (2010-2013), IR: Olga Amaral
Use of next-generation-sequencing (NGS) as an approach for the 
diagnosis of LSDs
Future 
plans
To develop a next generation sequencing (NGS) based workflow for the 
identification of exon-variations in a group of genes involved in lysosomal
function.
Aim
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Uncharacterized patients presenting symptoms associated with LSDs
The use of next generation sequencing in this group of patients with suspected LSD
but no definitive diagnosis would be the ideal approach to search for the genetic
basis of disease in these individuals
In the scope of Comissão Coordenadora do Tratamento das Doenças 
Lisossomais de Sobrecarga (CCTDLS) that operates under INSA 
coordination - Despacho n.º 2545/2013
Target
U1 snRNA-mediated Gene Therapeutic Approach in ULD patient-derived fibroblasts. 
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Unverricht- Lundborg disease - c.66G>A (CSTB gene)
Splicing Therapeutics - antisense oligonucleotide and U1snRNA mediated 
therapeutic strategies
Development of innovative therapies for LSDs
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Matos et al. under preparation
No correction
5’ AGCCGGCTGCTCACCTGCGCCATCGCCG 3’ 
Exon 1 Intron 1 Exon 2
354 bp
Development of innovative therapies for LSDs
Antisense Oligonucleotide Therapeutic Approach in ULD patient-derived fibroblasts. 
Unverricht- Lundborg disease - c.66G>A (CSTB gene)
Splicing Therapeutics - antisense oligonucleotide and U1snRNA mediated 
therapeutic strategies
M NC HC 5
ULD patient (LNA nM)
10025 500
500 bp
100 bp
1 2
21 354 bp
Intron 1
Anti - Cystatin B
ULD Patient
(LNA nM)
Control 
(LNA nM)
1000
Anti - α-Tubulin
11 kD
50 kD
0
Correct splicing
Successful correction of the aberrant transcript 
Matos et al. under preparation
Splicing Therapeutics - Antisense oligonucleotide and U1snRNA mediated 
therapeutic strategies
Development of innovative therapies for LSDs
Antisense Oligonucleotides treatment of
patient’s fibroblasts
M B CT DT 30 5050 100
AMO (µM) LNA (nM)
500 pb
Mucopolysaccharidosis type II c.1122C>T  (IDS gene)
No correction
Development of antisense therapeutic approaches remains 
a challenge in genes under fine regulation mechanisms as 
is the case of IDS gene.
Matos et al. under preparation
Mucopolysaccharidosis type IIIC c.234+1G>A (HGSNAT gene)
A partial recovery was achieved with a modified
U1 snRNA that completely matches the splice
donor site.
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Mini WT ex2
U1 snRNA-mediated Gene Therapeutic Approach in MPS IIIC patient-derived fibroblasts. 
Splicing Therapeutics - Antisense oligonucleotide and U1snRNA mediated 
therapeutic strategies
Development of innovative therapies for LSDs
U1 wt
HGSNAT exon 2: 
wt splice donor siteCACguauguau…
GUCcauucaua
Exon 2
Splice donor site
5’
3’
HGSNAT exon 2: mutated splice donor site
(c.234+1G>A)5’…CACauauguau…
3’…GUC tauucaua…
3’…GUGtauucaua…
U1 sup 1 (+1T)
U1 sup 2 (-1G +1T)
3’…GUGcauacaua… U1 sup 3 (-1G +4A)
3’…GUGtauacaua… U1 sup 4 (-1G +1T +4A)
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Matos et al. submitted
Mutations under study:
Mucopolysaccharidosis I: c.1650+5G>A  (IDUA gene)
Mucolipidosis III: c.3335+6T>G (GNPTAB gene)
Development of innovative therapies for LSDs
3 U1 variants were constructed for c.1650+5G>A 
2 U1 mutant vectors were constructed c.3335+6T>G 
transfected using Lipofectamine LTX
No correction
Splicing Therapeutics - Antisense oligonucleotide and U1snRNA mediated therapeutic 
strategies
Novel approach: U1 lentivirus plasmid will be used to generate through mutagenesis 
the same U1 mutant vectors that will be used in a model cell line with mutation-
disease minigenes as well as directly in patient’s fibroblasts through the transduction 
lentiviral technique. 
Substrate Reduction Therapy for Mucopolysaccharidoses through RNAi
Development of innovative therapies for LSDs
RNAi-dependent strategy based 
Selective downregulation of genes involved in the 
biosynthesis of the glycosaminoglycans (GAGs) 
that accumulate in patients suffering from 
Mucopolysaccharidoses.
WorkPlan
• Design specific siRNAs targeting genes involved in the biosynthesis of 
GAGs. 
– Targets: 
• CHSY1, CHPF e CHSY3; 
• EXTL2 e EXTL3; 
• XYLT1,XYLT2,GALTI, e GALTII
Development of innovative therapies for LSDs
Substrate Reduction Therapy for Mucopolysaccharidoses through RNAi
• Evaluate the effect of each specific siRNA in the 
mRNA expression levels and in its target protein 
expression levels. 
• Evaluate the effect of each specific siRNA and/or 
combination of individual siRNAs on the 
intralysosomal accumulation of GAGs in MPS 
patients’ cell lines. 
mRNA
GAGs
Future directions...
• Design a proper siRNA delivery strategy for therapeutic purposes
Development of innovative therapies for LSDs
• In vivo evaluation in animal models. 
These experiments will greatly benefit with 
our integration in CECA. 
Future directions: generation of iPSCells as disease specific cellular models for LSDs
Figures: Grskovic et al, 2011, Nat Rev Drug Discovery, 10:915-929
Generation of disease specific cell-targets
CECA might provide a favorable environment 
for fostering part of this work
Future directions : iPSCs as disease specific cellular models for LSDs
Figure from: Parenti et al, 2013, International J Molecular Med, 31(1), 11-20
